Biological therapies for cardiac arrhythmias: Can genes and cells replace drugs and devices?

Circulation Research

Volumn 106, Issue 4, 2010, Pages 674-685

  Cho, Hee Cheol ^a   Marbán, Eduardo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Bradycardia; Cell therapy; Gene therapy; Tachycardia

Indexed keywords

BIOLOGICAL PRODUCT; GENE PRODUCT;

BIOLOGICAL THERAPY; BRADYCARDIA; CELL THERAPY; GENE THERAPY; HEART ARRHYTHMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TACHYCARDIA;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BIOLOGICAL CLOCKS; CELL TRANSPLANTATION; ELECTROCARDIOGRAPHY; GENE THERAPY; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; TREATMENT OUTCOME;

EID: 77949378885     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.212936     Document Type: Review

References (100)

1. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82:1106-1116.
2. Echt DS, Liebson PR, Mitchell LB, Peters RW, ObiasManno D, Barker AH, Arensberg D, Baker A, Friedman L, Green HL, Huther ML, Richardson DW. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
3. Siebels J, Cappato R, Ruppel R, Schneider MA, Kuck KH. Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators. Am J Cardiol. 1993;72:109F-113F.
4. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7-12.
5. Falk RH. Atrial fibrillation. N Engl J Med. 2001;344:1067-1078.
6. Richardson AW, Josephson ME. Ablation of ventricular tachycardia in the setting of coronary artery disease. Curr Cardiol Rep. 1999;1: 157-164.
7. Bernstein AD, Parsonnet V. Survey of cardiac pacing and implanted defibrillator practice patterns in the United States in 1997. Pacing Clin Electrophysiol. 2001;24:842-855.
8. Khand AU, Rankin AC, Kaye GC, Cleland JG. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J. 2000;21:614-632.
9. Pelargonio G, Prystowsky EN. Rate versus rhythm control in the management of patients with atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2005;2:514-521.
10. Donahue JK, Heldman AW, Fraser H, McDonald AD, Miller JM, Rade JJ, Eschenhagen T, Marban E. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med. 2000;6:1395-1398.
11. Donahue JK, Kikkawa K, Thomas AD, Marban E, Lawrence JH. Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther. 1998; 5:630-634.
12. Nagata K, Marban E, Lawrence JH, Donahue JK. Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. J Mol Cell Cardiol. 2001;33:575-580.
13. Bauer A, McDonald AD, Nasir K, Peller L, Rade JJ, Miller JM, Heldman AW, Donahue JK. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation. 2004;110:3115-3120.
14. Beguin P, Nagashima K, Gonoi T, Shibasaki T, Takahashi K, Kashima Y, Ozaki N, Geering K, Iwanaga T, Seino S. Regulation of Ca2 + channel expression at the cell surface by the small G-protein kir/Gem. Nature. 2001;411:701-706.
15. Murata M, Cingolani E, McDonald AD, Donahue JK, Marban E. Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart. Circ Res. 2004;95:398-405.
16. Bunch TJ, Mahapatra S, Bruce GK, Johnson SB, Miller DV, Horne BD, Wang XL, Lee HC, Caplice NM, Packer DL. Impact of transforming growth factor-beta1 on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. Circulation. 2006; 113:2485-2494.
17. Wright M, Haissaguerre M, Knecht S, Matsuo S, O'Neill MD, Nault I, Lellouche N, Hocini M, Sacher F, Jais P. State of the art: catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19: 583-592.
18. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002;17:43-51.
19. Johns DC, Nuss HB, Chiamvimonvat N, Ramza BM, Marban E, Lawrence JH. Adenovirus-mediated expression of a voltage-gated potassium channel in vitro (rat cardiac myocytes) and in vivo (rat liver). A novel strategy for modifying excitability. J Clin Invest. 1995;96: 1152-1158.
20. Nuss HB, Johns DC, Kaab S, Tomaselli GF, Kass D, Lawrence JH, Marban E. Reversal of potassium channel deficiency in cells from failing hearts by adenoviral gene transfer: a prototype for gene therapy for disorders of cardiac excitability and contractility. Gene Ther. 1996; 3:900-912.
21. Nuss HB, Marban E, Johns DC. Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes. J Clin Invest. 1999;103:889-896.
22. Hoppe UC, Marban E, Johns DC. Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, HERG and KCNE1. Proc Natl Acad Sci USA. 2001;98: 5335-5340.
23. Sasano T, McDonald AD, Kikuchi K, Donahue JK. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med. 2006; 12:1256-1258.
24. Hoppe UC, Johns DC, Marban E, O'Rourke B. Manipulation of cellular excitability by cell fusion: effects of rapid introduction of transient outward K+ current on the guinea pig action potential. Circ Res. 1999;84:964-972.
25. Mitcheson JS, Hancox JC, Levi AJ. Cultured adult cardiac myocytes: future applications, culture methods, morphological and electrophysiological properties. Cardiovasc Res. 1998;39:280-300.
26. Hoppe UC, Marban E, Johns DC. Molecular dissection of cardiac repolarization by in vivo Kv4.3 gene transfer. J Clin Invest. 2000;105: 1077-1084.
27. Ruan Y, Liu N, Priori SG. Sodium channel mutations and arrhythmias. Nat Rev Cardiol. 2009;6:337-348.
28. Brunner M, Kodirov SA, Mitchell GF, Buckett PD, Shibata K, Folco EJ, Baker L, Salama G, Chan DP, Zhou J, Koren G. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. Am J Physiol. 2003;285:H194-H203.
29. Kodirov SA, Brunner M, Busconi L, Koren G. Long-term restitution of 4-aminopyridine-sensitive currents in Kv1DN ventricular myocytes using adeno-associated virus-mediated delivery of Kv1.5. FEBS Lett. 2003;550:74-78.
30. Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther. 2004; 9(suppl 1):S85-S97.
31. Brooks CM, Lu H-H. The Sinoatrial Pacemaker of the Heart. Springfield, Ill: Charles C. Thomas; 1972.
32. Kusumoto FM, Goldschlager N. Cardiac pacing. N Engl J Med. 1996; 334:89-97.
33. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statistics\2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
34. Henrikson CA, Brinker JA. How to prevent, recognize, and manage complications of lead extraction. Part I: avoiding lead extraction-infectious issues. Heart Rhythm. 2008;5:1083-1087.
35. Edelberg JM, Aird WC, Rosenberg RD. Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA. J Clin Invest. 1998;101:337-343.
36. Edelberg JM, Huang DT, Josephson ME, Rosenberg RD. Molecular enhancement of porcine cardiac chronotropy. Heart. 2001;86:559-562.
37. Miake J, Marban E, Nuss HB. Biological pacemaker created by gene transfer. Nature. 2002;419:132-133.
38. Schram G, Pourrier M, Melnyk P, Nattel S. Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res. 2002;90:939-950.
39. Kubo Y, Baldwin TJ, Jan YN, Jan LY. Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature. 1993;362:127-133.
40. Tinker A, Jan YN, Jan LY. Regions responsible for the assembly of inwardly rectifying potassium channels. Cell. 1996;87:857-868.
41. Irisawa H, Brown HF, Giles W. Cardiac pacemaking in the sinoatrial node. Physiol Rev. 1993;73:197-227.
42. Boyett MR, Honjo H, Kodama I. The sinoatrial node, a heterogeneous pacemaker structure. Cardiovasc Res. 2000;47:658-687.
43. DiFrancesco D. Serious workings of the funny current. Prog Biophys Mol Biol. 2006;90:13-25.
44. Baruscotti M, Difrancesco D. Pacemaker channels. Ann N Y Acad Sci. 2004;1015:111-121.
45. Sekar RB, Kizana E, Cho HC, Molitoris JM, Hesketh GG, Eaton BP, Marban E, Tung L. IK1 heterogeneity affects genesis and stability of spiral waves in cardiac myocyte monolayers. Circ Res. 2009;104: 355-364.
46. Brown HF, Kimura J, Noble D, Noble SJ, Taupignon A. The ionic currents underlying pacemaker activity in rabbit sino-atrial node: experimental results and computer simulations. Proc R Soc Lond B Biol Sci. 1984;222:329-347.
47. Miake J, Marban E, Nuss HB. Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression. J Clin Invest. 2003;111:1529-1536.
48. Brugada P, Wellens HJ. Early afterdepolarizations: role in conduction block, "prolonged repolarization-dependent reexcitation," and tachyarrhythmias in the human heart. Pacing Clin Electrophysiol. 1985; 8:889-896.
49. January CT, Moscucci A. Cellular mechanisms of early afterdepolar- izations. Ann N Y Acad Sci. 1992;644:23-32.
50. Ennis IL, Li RA, Murphy AM, Marban E, Nuss HB. Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility. J Clin Invest. 2002;109:393-400.
51. Baruscotti M, Bucchi A, Difrancesco D. Physiology and pharmacology of the cardiac pacemaker ("funny") current. Pharmacol Ther. 2005;107: 59-79.
52. Plotnikov AN, Sosunov EA, Qu J, Shlapakova IN, Anyukhovsky EP, Liu L, Janse MJ, Brink PR, Cohen IS, Robinson RB, Danilo P Jr, Rosen MR. Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation. 2004;109:506-512.
53. Qu J, Plotnikov AN, Danilo P Jr, Shlapakova I, Cohen IS, Robinson RB, Rosen MR. Expression and function of a biological pacemaker in canine heart. Circulation. 2003;107:1106-1109.
54. Tse HF, Xue T, Lau CP, Siu CW, Wang K, Zhang QY, Tomaselli GF, Akar FG, Li RA. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation. 2006;114:1000-1011.
55. Kashiwakura Y, Cho HC, Barth AS, Azene E, Marban E. Gene transfer of a synthetic pacemaker channel into the heart: a novel strategy for biological pacing. Circulation. 2006;114:1682-1686.
56. Campos SK, Barry MA. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther. 2007;7: 189-204.
57. Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res. 2008;102:1458-1470.
58. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004;95:9-20.
59. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev. 2008;8:726-736.
60. Potapova I, Plotnikov A, Lu Z, Danilo P Jr, Valiunas V, Qu J, Doronin S, Zuckerman J, Shlapakova IN, Gao J, Pan Z, Herron AJ, Robinson RB, Brink PR, Rosen MR, Cohen IS. Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res. 2004;94: 952-959.
61. Plotnikov AN, Shlapakova I, Szabolcs MJ, Danilo P Jr, Lorell BH, Potapova IA, Lu Z, Rosen AB, Mathias RT, Brink PR, Robinson RB, Cohen IS, Rosen MR. Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart. Circulation. 2007;116:706-713.
62. van der Velden HM, Jongsma HJ. Cardiac gap junctions and connexins: their role in atrial fibrillation and potential as therapeutic targets. Car-diovasc Res. 2002;54:270-279.
63. Rosen AB, Kelly DJ, Schuldt AJ, Lu J, Potapova IA, Doronin SV, Robichaud KJ, Robinson RB, Rosen MR, Brink PR, Gaudette GR, Cohen IS. Finding fluorescent needles in the cardiac haystack: tracking human mesenchymal stem cells labeled with quantum dots for quantitative in vivo three-dimensional fluorescence analysis. Stem Cells. 2007; 25:2128-2138.
64. Chang MG, Tung L, Sekar RB, Chang CY, Cysyk J, Dong P, Marban E, Abraham MR. Proarrhythmic potential of mesenchymal stem cell transplantation revealed in an in vitro coculture model. Circulation. 2006; 113:1832-1841.
65. Cho HC, Kashiwakura Y, Marban E. Creation of a biological pacemaker by cell fusion. Circ Res. 2007;100:1112-1115.
66. Shirahata S, Katakura Y, Teruya K. Cell hybridization, hybridomas, and human hybridomas. Methods Cell Biol. 1998;57:111-145.
67. Lentz BR, Lee JK. Poly(ethylene glycol) (PEG)-mediated fusion between pure lipid bilayers: a mechanism in common with viral fusion and secretory vesicle release? Mol Membr Biol. 1999;16:279-296.
68. Alvarez-Dolado M, Pardal R, Garcia-Verdugo JM, Fike JR, Lee HO, Pfeffer K, Lois C, Morrison SJ, Alvarez-Buylla A. Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepa-tocytes. Nature. 2003;425:968-973.
69. Gussoni E, Bennett RR, Muskiewicz KR, Meyerrose T, Nolta JA, Gilgoff I, Stein J, Chan YM, Lidov HG, Bonnemann CG, Von Moers A, Morris GE, Den Dunnen JT, Chamberlain JS, Kunkel LM, Weinberg K. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. J Clin Invest. 2002;110:807-814.
70. Weimann JM, Johansson CB, Trejo A, Blau HM. Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant. Nat Cell Biol. 2003;5:959-966.
71. Hoffman LM, Carpenter MK. Characterization and culture of human embryonic stem cells. Nat Biotechnol. 2005;23:699-708.
72. He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res. 2003;93:32-39.
73. Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, Livne E, Binah O, Itskovitz-Eldor J, Gepstein L. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. 2001;108:407-414.
74. Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S, Hassink R, van der Heyden M, Opthof T, Pera M, de la Riviere AB, Passier R, Tertoolen L. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation. 2003;107:2733-2740.
75. Xu C, Police S, Rao N, Carpenter MK. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res. 2002;91:501-508.
76. Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, Huber I, Satin J, Itskovitz-Eldor J, Gepstein L. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Bio-technol. 2004;22:1282-1289.
77. Xue T, Cho HC, Akar FG, Tsang SY, Jones SP, Marban E, Tomaselli GF, Li RA. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation. 2005;111:11-20.
78. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30-e41.
79. Anversa P, Kajstura J, Leri A, Bolli R. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation. 2006;113: 1451-1463.
80. Beltrami AP, Barlucchi L, Torella D, Baker M, Limana F, Chimenti S, Kasahara H, Rota M, Musso E, Urbanek K, Leri A, Kajstura J, Nadal-Ginard B, Anversa P. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114:763-776.
81. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisen J. Evidence for cardiomyocyte renewal in humans. Science. 2009;324:98-102.
82. Messina E, De Angelis L, Frati G, Morrone S, Chimenti S, Fiordaliso F, Salio M, Battaglia M, Latronico MV, Coletta M, Vivarelli E, Frati L, Cossu G, Giacomello A. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res. 2004;95:911-921.
83. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, Gia-comello A, Abraham MR, Marban E. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115:896-908.
84. Robertson JA. Human embryonic stem cell research: ethical and legal issues. Nat Rev Genet. 2001;2:74-78.
85. Gerecht-Nir S, Itskovitz-Eldor J. Cell therapy using human embryonic stem cells. Transpl Immunol. 12:203-209, 2004.
86. Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. Stem Cells. 2001;19:193-204.
87. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299-307.
88. Ren D, Navarro B, Xu H, Yue L, Shi Q, Clapham DE. A prokaryotic voltage-gated sodium channel. Science. 2001;294:2372-2375.
89. Kurejova M, Uhrik B, Sulova Z, Sedlakova B, Krizanova O, Lacinova L. Changes in ultrastructure and endogenous ionic channels activity during culture of HEK293 cell line. Eur J Pharmacol. 567:10-18, 2007.
90. Varghese A, Tenbroek EM, Coles J Jr, Sigg DC. Endogenous channels in HEK cells and potential roles in HCN ionic current measurements. Prog Biophys Mol Biol. 90:26-37, 2006.
91. Cho HC, Kashiwakura Y, Marban E. Conversion of non-excitable cells to self-contained biological pacemakers. Circulation. 2005;112:II-307. Abstract.
92. Lakatta EG, Maltsev VA, Bogdanov KY, Stern MD, Vinogradova TM. Cyclic variation of intracellular calcium: a critical factor for cardiac pacemaker cell dominance. Circ Res. 2003;92:e45-e50.
93. Lakatta EG, Vinogradova TM, Maltsev VA. The missing link in the mystery of normal automaticity of cardiac pacemaker cells. Ann N Y Acad Sci. 2008;1123:41-57.
94. Kass RS, Tsien RW. Fluctuations in membrane current driven by intracellular calcium in cardiac Purkinje fibers. Biophys J. 1982;38:259-269.
95. Das MK, Dandamudi G, Steiner H. Role of ablation therapy in ventricular arrhythmias. Cardiol Clin. 2008;26:459-479.
96. Kizana E, Chang CY, Cingolani E, Ramirez-Correa GA, Sekar RB, Abraham MR, Ginn SL, Tung L, Alexander IE, Marban E. Gene transfer of connexin43 mutants attenuates coupling in cardiomyocytes: novel basis for modulation of cardiac conduction by gene therapy. Circ Res. 2007;100:1597-1604.
97. Lau DH, Clausen C, Sosunov EA, Shlapakova IN, Anyukhovsky EP, Danilo P Jr, Rosen TS, Kelly C, Duffy HS, Szabolcs MJ, Chen M, Robinson RB, Lu J, Kumari S, Cohen IS, Rosen MR. Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study. Circulation. 2009;119: 19-27.
98. + channel isoform preserves normal conduction in a depolarized cardiac syncytium. Cardiovasc Res. 2009;81:528-535.
99. Mitani K, Graham FL, Caskey CT, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci USA. 1995;92:3854-3858.
100. Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther. 2008;8:911-922.